Daiichi Sankyo ( Daiichi Sankyo )

Daiichi Sankyo

Daiichi Sankyo's picture

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

Daiichi Sankyo press release, blog etc

03/07/2018 - 20:01 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
02/26/2018 - 18:54 Daiichi Sankyo Announces NDA submission in Japan of Esaxerenone for Treatment of Hypertension
02/26/2018 - 17:48 Daiichi Sankyo Reports Rupture of Liquid Storage Tank at Kitamoto Facility of Kitasato Daiichi Sankyo Vaccine
02/22/2018 - 20:07 Daiichi Sankyo Initiates Phase 1 Study of DS-1062 in Patients with Advanced Non-Small Cell Lung Cancer
02/22/2018 - 18:36 Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2018
02/22/2018 - 00:15 Daiichi Sankyo Submits Application for Additional Indication and Dosage for Diagnogreen for Injection 25 mg in Japan
02/15/2018 - 01:23 Daiichi Sankyo Submits Marketing Application for Mirogabalin in Japan
02/06/2018 - 17:48 Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
02/01/2018 - 21:09 Daiichi Sankyo Selected for Silver Class of RobecoSAM Sustainability Award 2018
02/01/2018 - 21:08 Daiichi Sankyo Announces Update on Amgen Inc.s Phase 3 Clinical Trial Evaluating Denosumab as Adjuvant Breast Cancer Treatment
01/19/2018 - 02:52 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
12/14/2017 - 02:57 Winners of 10th Manpei Suzuki International Prize for Diabetes Research and 11th Manpei Suzuki Prize for Diabetes Care and Education Announced
12/12/2017 - 20:49 Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
12/12/2017 - 18:06 Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
12/07/2017 - 18:35 Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Breast Cancer at San Antonio Breast Cancer Symposium
12/06/2017 - 21:54 Daiichi Sankyos Subsidiary Daiichi Sankyo Espha to Launch New Generic Drugs
11/30/2017 - 20:39 Daiichi Sankyo and Translational Sciences Conclude Agreement, after Successful Phase 1a Trial, as Part of Daiichi Sankyo Portfolio Prioritization
11/29/2017 - 23:33 Daiichi Sankyo to Absorb Japan Research Subsidiary, Asubio Pharma Co., Ltd.